|
1
|
Cheng L, Bao S and Rich JN: Potential
therapeutic implications of cancer stem cells in glioblastoma.
Biochem Pharmacol. 80:654–665. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Orza A, Soriţău O, Tomuleasa C, Olenic L,
Florea A, Pana O, Bratu I, Pall E, Florian S, Casciano D, et al:
Reversing chemore-sistance of malignant glioma stem cells using
gold nanoparticles. Int J Nanomedicine. 8:689–702. 2013. View Article : Google Scholar :
|
|
3
|
Higgins DM, Wang R, Milligan B, Schroeder
M, Carlson B, Pokorny J, Cheshier SH, Meyer FB, Weissman IL,
Sarkaria JN, et al: Brain tumor stem cell multipotency correlates
with nanog expression and extent of passaging in human glioblastoma
xenografts. Oncotarget. 4:792–801. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Neman J and Jandial R: Decreasing glioma
recurrence through adjuvant cancer stem cell inhibition. Biologics.
4:157–162. 2010.PubMed/NCBI
|
|
5
|
Johannessen TC, Bjerkvig R and Tysnes BB:
DNA repair and cancer stem-like cells - potential partners in
glioma drug resistance? Cancer Treat Rev. 34:558–567. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Beier D, Schriefer B, Brawanski K, Hau P,
Weis J, Schulz JB and Beier CP: Efficacy of clinically relevant
temozolomide dosing schemes in glioblastoma cancer stem cell lines.
J Neurooncol. 109:45–52. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Auffinger B, Tobias AL, Han Y, Lee G, Guo
D, Dey M, Lesniak MS and Ahmed AU: Conversion of differentiated
cancer cells into cancer stem-like cells in a glioblastoma model
after primary chemotherapy. Cell Death Differ. 21:1119–1131. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Persano L, Rampazzo E, Basso G and Viola
G: Glioblastoma cancer stem cells: Role of the microenvironment and
therapeutic targeting. Biochem Pharmacol. 85:612–622. 2013.
View Article : Google Scholar
|
|
9
|
Sales JM and Resurreccion AV: Resveratrol
in peanuts. Crit Rev Food Sci Nutr. 54:734–770. 2014. View Article : Google Scholar
|
|
10
|
Borriello A, Bencivenga D, Caldarelli I,
Tramontano A, Borgia A, Zappia V and Della Ragione F: Resveratrol:
From basic studies to bedside. Cancer Treat Res. 159:167–184. 2014.
View Article : Google Scholar
|
|
11
|
Pallàs M, Ortuño-Sahagún D, Benito-Andrés
P, Ponce-Regalado MD and Rojas-Mayorquín AE: Resveratrol in
epilepsy: Preventive or treatment opportunities? Front Biosci
(Landmark Ed). 19:1057–1064. 2014. View
Article : Google Scholar
|
|
12
|
Aggarwal BB, Bhardwaj A, Aggarwal RS,
Seeram NP, Shishodia S and Takada Y: Role of resveratrol in
prevention and therapy of cancer: Preclinical and clinical studies.
Anticancer Res. 24:2783–2840. 2004.PubMed/NCBI
|
|
13
|
Harikumar KB and Aggarwal BB: Resveratrol:
A multitargeted agent for age-associated chronic diseases. Cell
Cycle. 7:1020–1035. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Delmas D, Solary E and Latruffe N:
Resveratrol, a phytochemical inducer of multiple cell death
pathways: Apoptosis, autophagy and mitotic catastrophe. Curr Med
Chem. 18:1100–1121. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yuan Y, Xue X, Guo RB, Sun XL and Hu G:
Resveratrol enhances the antitumor effects of temozolomide in
glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway. CNS
Neurosci Ther. 18:536–546. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang H, Lin H, Zhang X and Li J:
Resveratrol reverses temo-zolomide resistance by downregulation of
MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
Oncol Rep. 27:2050–2056. 2012.PubMed/NCBI
|
|
17
|
Aldaz B, Sagardoy A, Nogueira L, Guruceaga
E, Grande L, Huse JT, Aznar MA, Díez-Valle R, Tejada-Solís S,
Alonso MM, et al: Involvement of miRNAs in the differentiation of
human glioblastoma multiforme stem-like cells. PLoS One.
8:e770982013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Romanelli S, Perego P, Pratesi G, Carenini
N, Tortoreto M and Zunino F: In vitro and in vivo interaction
between cisplatin and topotecan in ovarian carcinoma systems.
Cancer Chemother Pharmacol. 41:385–390. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang YP, Chang YL, Huang PI, Chiou GY,
Tseng LM, Chiou SH, Chen MH, Chen MT, Shih YH, Chang CH, et al:
Resveratrol suppresses tumorigenicity and enhances radiosensitivity
in primary glioblastoma tumor initiating cells by inhibiting the
STAT3 axis. J Cell Physiol. 227:976–993. 2012. View Article : Google Scholar
|
|
20
|
Gedye C and Ailles L: Isolation and
characterization of cancer stem cells in vitro. Methods Mol Biol.
946:181–204. 2013. View Article : Google Scholar
|
|
21
|
Roos WP and Kaina B: DNA damage-induced
cell death: From specific DNA lesions to the DNA damage response
and apoptosis. Cancer Lett. 332:237–248. 2013. View Article : Google Scholar
|
|
22
|
Ponnala S, Veeravalli KK, Chetty C, Dinh
DH and Rao JS: Regulation of DNA repair mechanism in human glioma
xenograft cells both in vitro and in vivo in nude mice. PLoS One.
6:e261912011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Silber JR, Bobola MS, Blank A and
Chamberlain MC: O(6)-methylguanine-DNA methyltransferase in glioma
therapy: Promise and problems. Biochim Biophys Acta. 1826:71–82.
2012.PubMed/NCBI
|
|
24
|
Park I and Avraham HK: Cell
cycle-dependent DNA damage signaling induced by ICRF-193 involves
ATM, ATR, CHK2, and BRCA1. Exp Cell Res. 312:1996–2008. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Eyler CE, Wu Q, Yan K, MacSwords JM,
Chandler-Militello D, Misuraca KL, Lathia JD, Forrester MT, Lee J,
Stamler JS, et al: Glioma stem cell proliferation and tumor growth
are promoted by nitric oxide synthase-2. Cell. 146:53–66. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lin CJ, Lee CC, Shih YL, Lin TY, Wang SH,
Lin YF and Shih CM: Resveratrol enhances the therapeutic effect of
temozolomide against malignant glioma in vitro and in vivo by
inhibiting autophagy. Free Radic Biol Med. 52:377–391. 2012.
View Article : Google Scholar
|
|
27
|
Johannessen TC and Bjerkvig R: Molecular
mechanisms of temozolomide resistance in glioblastoma multiforme.
Expert Rev Anticancer Ther. 12:635–642. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Leone S, Basso E, Polticelli F and Cozzi
R: Resveratrol acts as a topoisomerase II poison in human glioma
cells. Int J Cancer. 131:E173–E178. 2012. View Article : Google Scholar
|
|
29
|
Srivastava M and Raghavan SC: DNA
double-strand break repair inhibitors as cancer therapeutics. Chem
Biol. 22:17–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Aparicio T, Baer R and Gautier J: DNA
double-strand break repair pathway choice and cancer. DNA Repair
(Amst). 19:169–175. 2014. View Article : Google Scholar
|
|
31
|
Villalva C, Cortes U, Wager M, Tourani JM,
Rivet P, Marquant C, Martin S, Turhan AG and Karayan-Tapon L:
O6-Methyl-guanine-methyltransferase (MGMT) promoter
methylation status in glioma stem-like cells is correlated to
temozolomide sensitivity under differentiation-promoting
conditions. Int J Mol Sci. 13:6983–6994. 2012. View Article : Google Scholar
|
|
32
|
Haince JF, McDonald D, Rodrigue A, Déry U,
Masson JY, Hendzel MJ and Poirier GG: PARP1-dependent kinetics of
recruitment of MRE11 and NBS1 proteins to multiple DNA damage
sites. J Biol Chem. 283:1197–1208. 2008. View Article : Google Scholar
|
|
33
|
Gobbini E, Cesena D, Galbiati A, Lockhart
A and Longhese MP: Interplays between ATM/Tel1 and ATR/Mec1 in
sensing and signaling DNA double-strand breaks. DNA Repair (Amst).
12:791–799. 2013. View Article : Google Scholar
|
|
34
|
Cooper TJ, Wardell K, Garcia V and Neale
MJ: Homeostatic regulation of meiotic DSB formation by ATM/ATR. Exp
Cell Res. 329:124–131. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Speidel D: The role of DNA damage
responses in p53 biology. Arch Toxicol. 89:501–517. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shimada M and Nakanishi M: Response to DNA
damage: Why do we need to focus on protein phosphatases? Front
Oncol. 3:82013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Loewer A, Karanam K, Mock C and Lahav G:
The p53 response in single cells is linearly correlated to the
number of DNA breaks without a distinct threshold. BMC Biol.
11:1142013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kolb JP: Mechanisms involved in the pro-
and anti-apoptotic role of NO in human leukemia. Leukemia.
14:1685–1694. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nakano I: Stem cell signature in
glioblastoma: Therapeutic development for a moving target. J
Neurosurg. 122:324–330. 2015. View Article : Google Scholar
|
|
40
|
Sato A, Okada M, Shibuya K, Watanabe E,
Seino S, Suzuki K, Narita Y, Shibui S, Kayama T and Kitanaka C:
Resveratrol promotes proteasome-dependent degradation of Nanog via
p53 activation and induces differentiation of glioma stem cells.
Stem Cell Res (Amst). 11:601–610. 2013. View Article : Google Scholar
|
|
41
|
Li GH, Wei H, Lv SQ, Ji H and Wang DL:
Knockdown of STAT3 expression by RNAi suppresses growth and induces
apoptosis and differentiation in glioblastoma stem cells. Int J
Oncol. 37:103–110. 2010.PubMed/NCBI
|
|
42
|
Yang L, Guo H, Dong L, Wang L, Liu C and
Wang X: Tanshinone IIA inhibits the growth, attenuates the stemness
and induces the apoptosis of human glioma stem cells. Oncol Rep.
32:1303–1311. 2014.PubMed/NCBI
|
|
43
|
Liu M, Inoue K, Leng T, Guo S and Xiong
ZG: TRPM7 channels regulate glioma stem cell through STAT3 and
Notch signaling pathways. Cell Signal. 26:2773–2781. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lin J, Jin X, Rothman K, Lin HJ, Tang H
and Burke W: Modulation of signal transducer and activator of
transcription 3 activities by p53 tumor suppressor in breast cancer
cells. Cancer Res. 62:376–380. 2002.PubMed/NCBI
|
|
45
|
Yang F, Zhang W, Li D and Zhan Q: Gadd45a
suppresses tumor angiogenesis via inhibition of the mTOR/STAT3
protein pathway. J Biol Chem. 288:6552–6560. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gray GK, McFarland BC, Nozell SE and
Benveniste EN: NF-κB and STAT3 in glioblastoma: Therapeutic targets
coming of age. Expert Rev Neurother. 14:1293–1306. 2014. View Article : Google Scholar : PubMed/NCBI
|
